Help Us Get Emgality on the PBS – Here’s What’s Going On
One step forward – but we still have work to do.
Emgality (Galcanezumab) is being considered again at the upcoming PBAC (Pharmaceutical Benefits Advisory Committee) meeting in July, to decide whether Emgality will be covered under the PBS (Pharmaceutical Benefits Scheme).
The PBAC will review the Emgality recommendation from 2 years ago, and decide whether to change the access conditions to mirror the Ajovy ones.
This would make Emgality more accessible to more people.
Right now, public comments are open until May 28. If you want to have your say and share your experience with migraine, you can do that via the link below.
Here’s how you can help:
-
Share your story via the PBAC public comment link before May 28.
- Contact your local MP - particularly if they're newly elected. As soon as they're sworn in, you can find their info here.
Together, we can push for real change and ensure migraine is taken seriously in Australia.